Halozyme Therapeutics Inc (HALO)
46.93
-0.39
(-0.82%)
USD |
NASDAQ |
Dec 20, 16:00
46.95
+0.02
(+0.04%)
After-Hours: 20:00
Halozyme Therapeutics Debt to Equity Ratio: 3.323 for Sept. 30, 2024
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Lexicon Pharmaceuticals Inc | 0.5596 |
| Novavax Inc | -0.3215 |
| Kura Oncology Inc | -- |
| TransMedics Group Inc | 2.422 |
| Pulmonx Corp | 0.3964 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 2.118B |
| Total Liabilities (Quarterly) | 1.665B |
| Shareholders Equity (Quarterly) | 452.70M |
| Current Ratio | 10.36 |
| Net Debt Paydown Yield | -0.02% |